Dried blood spots: A new tool for tuberculosis treatment optimization

Current Pharmaceutical Design

Volumn 17, Issue 27, 2011, Pages 2931-2939

  Vu, D H ^a,b,c   Alffenaar, J W C ^b   Edelbroek, P M ^d   Brouwers, J R B J ^a   Uges, D R A ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c HANOI UNIVERSITY OF PHARMACY   (Viet Nam)

^d STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

Dried blood spot; Optimization; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; BIOSAFETY; BLOOD SAMPLING; BLOOD VOLUME; CHROMATOGRAPHY; DRIED BLOOD SPOT; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; HEMATOCRIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 80053473777     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797470174     Document Type: Article

References (104)

1. World Health Organization. Global tuberculosis control: a short update to the 2009 report. 2009; Available at: http://whqlibdoc.who.int/publications/2009/9789241598866_eng.pdf. Accessed January, 2011.
2. Onozaki I, Raviglione M. Stopping tuberculosis in the 21st century: goals and strategies. Respirology 2010; 15(1): 32-43.
3. Suarez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, Ramos G, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359(9322): 1980-9.
4. Johannessen A. Dried blood spots in HIV monitoring: applications in resource-limited settings. Bioanalysis 2010; 2(11): 1893-908.
5. Benyshek DC. Use of dried blood spots: an ideal tool for medical anthropology in the field. J Diabetes Sci Technol 2010; 4(2): 255-7.
6. Hong Kong Chest Service/British Medical Research Council. Fiveyear follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136(6): 1339-42.
7. British Thoracic Society. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. Br J Dis Chest 1984; 78(4): 330-6.
8. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990; 112(6): 397-406.
9. Wilkinson D, Davies GR, Connolly C. Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994. Am J Public Health 1996; 86(0090-0036; 8): 1094-7.
10. World Health Organization report 2009. Global tuberculosis control - epidemilogy, strategy, finacing. 2009; Available at: http://whqlibdoc.who.int/publications/2009/9789241563802_eng.pdf. Accessed November, 2010.
11. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375(9728): 1830-43.
12. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 2009; 10(3): 381-401.
13. Dartois V, Barry CE. Clinical Pharmacology and Lesion Penetrating Properties of Second-and Third-Line Antituberculous Agents used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis. Curr Clin Pharmacol 2010 02/16(1574-8847).
14. Pasipanodya J, Gumbo T. An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future. Antimicrob Agents Chemother 2011; 55(1): 24-34.
15. Davies GR, Nuermberger EL. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis (Edinb) 2008; 88 Suppl 1: S65-74.
16. Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. European Journal of Clinical Microbiology & Infectious Diseases 2004; 23(4): 243-55.
17. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62(0012-6667; 15): 2169-83.
18. Unsalan S, Sancar M, Bekce B, et al. Therapeutic monitoring of isoniazid, pyrazinamide and rifampicin in tuberculosis patients using LC. Chromatographia 2005; 61(11-12): 595-8.
19. Rodriguez JC, Cebrian L, Ruiz M, Lopez M, Royo G. Mutant prevention concentration of isoniazid, rifampicin and rifabutin against Mycobacterium tuberculosis. Chemotherapy 2005; 51(2-3): 76-9.
20. Ray J, Gardiner I, Marriott D. Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med J 2003; 33(1444-0903; 5-6): 229-34.
21. Nijland HMJ, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clinical Infectious Diseases 2006; 43(7): 848-54.
22. Ruslami R, Nijland HMJ, Adhiarta IGN, et al. Pharmacokinetics of Antituberculosis Drugs in Pulmonary Tuberculosis Patients with Type 2 Diabetes. Antimicrob Agents Chemother 2010; 54(3): 1068-74.
23. Douglas JG, McLeod MJ. Pharmacokinetic factors in the modern drug treatment of tuberculosis. Clin Pharmacokinet 1999; 37(2): 127-46.
24. Yew WW. Therapeutic drug monitoring in antituberculosis chemotherapy. Ther Drug Monit 1998; 20(5): 469-72.
25. Elsherbiny D, Cohen K, Jansson B, Smith P, McIlleron H, Simonsson US. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV-and tuberculosis-infected South African patients. Eur J Clin Pharmacol 2009; 65(1): 71-80.
26. Breen RAM, Swaden L, Ballinger J, Lipman MCI. Tuberculosis and HIV co-infection - A practical therapeutic approach. Drugs 2006; 66(18): 2299-308.
27. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009; 14(8): 1039-43.
28. Breen RA, Miller RF, Gorsuch T, et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis 2006; 193(10): 1437-40.
29. [Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 1999; 28(3): 419-29; quiz 430.
30. Tappero JW, Bradford WZ, Agerton TB, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clinical Infectious Diseases 2005; 41(4): 461-9.
31. McIlleron H, Willemse M, Werely CJ, et al. Isoniazid Plasma Concentrations in a Cohort of South African Children with Tuberculosis: Implications for International Pediatric Dosing Guidelines. Clinical Infectious Diseases 2009; 48(11): 1547-53.
32. Holland DP, Hamilton CD, Weintrob AC, et al. Therapeutic Drug Monitoring of Antimycobacterial Drugs in Patients with Both Tuberculosis and Advanced Human Immunodeficiency Virus Infection. Pharmacotherapy 2009; 29(5): 503-10.
33. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 2009; 31(3): 327-36.
34. McDade TW, Williams S, Snodgrass JJ. What a drop can do: dried blood spots as a minimally invasive method for integrating biomarkers into population-based research. Demography 2007; 44(4): 899-25.
35. Bowen C. Automatable Processes and Future Directions in Dried Blood Spot Analysis. Am Lab 2010; 42(10): 11-4.
36. Li W, Tse FL. Dried blood spot sampling in combination with LCMS/ MS for quantitative analysis of small molecules. Biomed Chromatogr 2010; 24(1099-0801; 0269-3879; 1): 49-65.
37. Hoogtanders K, van der HJ, Christiaans M, van de PA, van HJ, Stolk L. Dried blood spot measurement of tacrolimus is promising for patient monitoring. Transplantation 2007; 83(0041-1337; 2): 237-8.
38. Leichtle AB, Ceglarek U, Witzigmann H, Gabel G, Thiery J, Fiedler GM. Potential of dried blood self-sampling for cyclosporine c(2) monitoring in transplant outpatients. J Transplant 2010; 2010: 201918.
39. Li JH, Burzynski JN, Lee YA, et al. Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. Chest 2004; 126(6): 1770-6.
40. Johannessen A, Troseid M, Calmy A. Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings. J Antimicrob Chemother 2009; 64(6): 1126-9.
41. [Kredo T, Van der Walt JS, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev 2009; (3)(3): CD007268.
42. Parker SP, Cubitt WD. The use of the dried blood spot sample in epidemiological studies. J Clin Pathol 1999; 52(9): 633-9.
43. [World Health Organization. Rapid advice: Treatment of tuberculosis in children. 2010; Available at: http:// whqlibdoc.who.int/publications/2010/9789241500449_eng.pdf. Accessed February, 2011.
44. Ramachandran G, Kumar AK, Swaminathan S. Pharmacokinetics of Anti-tuberculosis Drugs in Children. Indian J Pediatr 2010.
45. Graham SM. Treatment of paediatric TB: revised WHO guidelines. Paediatr Respir Rev 2011; 12(1): 22-6.
46. Pandya HC, Spooner N, Mulla H. Dried blood spots, pharmacokinetic studies and better medicines for children. Bioanalysis 2011; 3(7): 779-86.
47. Patel P, Mulla H, Tanna S, Pandya H. Facilitating pharmacokinetic studies in children: a new use of dried blood spots. Arch Dis Child 2010; 95(6): 484-7.
48. Ette EI, Williams PJ, Lane JR. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies. Ann Pharmacother 2004; 38(12): 2136-44.
49. [Guthrie R, Susi A. A Simple Phenylalanine Method for Detecting Phenylketonuria in Large Populations of Newborn Infants. Pediatrics 1963; 32(3): 338-&.
50. Wilcken B, Wiley V. Newborn screening. Pathology 2008; 40(2): 104-15.
51. Padilla CD, Therrell BL. Newborn screening in the Asia Pacific region. J Inherit Metab Dis 2007; 30(4): 490-506.
52. Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens 1. J Nutr 2001; 131(0022-3166; 0022-3166; 5): 1631S-6S.
53. Suyagh M, Collier PS, Millership JS, et al. Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. Pediatrics 2011; 127(2): e367-74.
54. Gervasini G, Benitez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol 2010; 66(8): 755-74.
55. Boer T, Wieling J, Meulman E, et al. Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers. Biomed Chromatogr 2011.
56. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry. Bioanalytical Method Validation. 2001.
57. Vu DH, Koster RA, Alffenaar JWC, Brouwers JRBJ, Uges DRA. Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. Journal of Chromatography B 2011; 879(15-16): 1063-70.
58. ter HR, Rosing H, van Gorp EC, et al. Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 867(1570-0232; 2): 205-12.
59. Denniff P, Spooner N. The effect of hematocrit on assay bias when using DBS samples for the quantitative bioanalysis of drugs. Bioanalysis 2010; 2(8): 1385-95.
60. van der Heijden J, de Beer Y, Hoogtanders K, et al. Therapeutic drug monitoring of everolimus using the dried blood spot method in combination with liquid chromatography-mass spectrometry. J Pharm Biomed Anal 2009; 50(4): 664-70.
61. Ntale M, Ogwal-Okeng JW, Mahindi M, Gustafsson LL, Beck O. A field-adapted sampling and HPLC quantification method for lumefantrine and its desbutyl metabolite in whole blood spotted on filter paper. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 876(1570-0232; 2): 261-5.
62. Ntale M, Mahindi M, Ogwal-Okeng JW, Gustafsson LL, Beck O. A field-adapted HPLC method for determination of amodiaquine and its metabolite in whole blood dried on filter paper. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 859(1570-0232; 1): 137-40.
63. Green MD, Mount DL, Nettey H. High-performance liquid chromatographic assay for the simultaneous determination of sulfadoxine and pyrimethamine from whole blood dried onto filter paper. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 767(1570-0232; 1): 159-62.
64. Koal T, Burhenne H, Romling R, Svoboda M, Resch K, Kaever V. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19(0951-4198; 21): 2995-3001.
65. Suyagh MF, Iheagwaram G, Kole PL, et al. Development and validation of a dried blood spot-HPLC assay for the determination of metronidazole in neonatal whole blood samples. Anal Bioanal Chem 2010; 397(1618-2650; 2): 687-93.
66. Liang X, Li Y, Barfield M, Ji QC. Study of dried blood spots technique for the determination of dextromethorphan and its metabolite dextrorphan in human whole blood by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877(1873-376; 8-9): 799-806.
67. Allanson AL, Cotton MM, Tettey JN, Boyter AC. Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring. J Pharm Biomed Anal 2007; 44(0731-7085; 4): 963-9.
68. Deglon J, Thomas A, Daali Y, et al. Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite. J Pharm Biomed Anal 2011; 54(2): 359-67.
69. Deglon J, Thomas A, Cataldo A, Mangin P, Staub C. On-line desorption of dried blood spot: A novel approach for the direct LC/MS analysis of micro-whole blood samples. J Pharm Biomed Anal 2009 05/01; 49(0731-7085; 4): 1034-9.
70. Abu-Rabie P, Spooner N. Direct quantitative bioanalysis of drugs in dried blood spot samples using a thin-layer chromatography mass spectrometer interface. Anal Chem 2009; 81(24): 10275-84.
71. [RE. New Directions in Whole Blood Analysis: Dried Blood Spot Analysis and Beyond. Lc Gc N Am 2011; 29(1): 14-+.
72. [Wilhelm AJ, den Burger JC, Vos RM, Chahbouni A, Sinjewel A. Analysis of cyclosporin A in dried blood spots using liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009 03/24(1873-376).
73. Wilhelm AJ, den Burger JCG, Chahbouni A, Vos RM, Sinjewel A. Analysis of mycophenolic acid in dried blood spots using reversed phase high performance liquid chromatography. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences 2009 NOV 15; 877(30): 3916-9.
74. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003 01/09; 348(1533-4406; 2): 119-28.
75. Antony SJ, Harrell V, Christie JD, Adams HG, Rumley RL. Clinical differences between pulmonary and extrapulmonary tuberculosis: a 5-year retrospective study. J Natl Med Assoc 1995; 87(0027-9684; 0027-9684; 3): 187-92.
76. Fujimoto T, Tsuda Y, Tawa R, Hirose S. Fluorescence polarization immunoassay of gentamicin or netilmicin in blood spotted on filter paper. Clin Chem 1989; 35(0009-9147; 5): 867-9.
77. Kolawole JA, Mustapha A. Improved RP-HPLC determination of quinine in plasma and whole blood stored on filter paper. Biopharm Drug Dispos 2000; 21(0142-2782; 9): 345-52.
78. [Holub M, Tuschl K, Ratschmann R, et al. Influence of hematocrit and localisation of punch in dried blood spots on levels of amino acids and acylcarnitines measured by tandem mass spectrometry. Clinica Chimica Acta 2006 11; 373(1-2): 27-31.
79. Adam BW, Alexander JR, Smith SJ, et al. Recoveries of phenylalanine from two sets of dried-blood-spot reference materials: prediction from hematocrit, spot volume, and paper matrix. Clin Chem 2000; 46(0009-9147; 0009-9147; 1): 126-8.
80. [Damen CW, Rosing H, Schellens JH, Beijnen JH. Application of dried blood spots combined with high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry for simultaneous quantification of vincristine and actinomycin-D. Anal Bioanal Chem 2009 04/24(1618-2650).
81. Malm M, Lindegardh N, Bergqvist Y. Automated solid-phase extraction method for the determination of piperaquine in capillary blood applied onto sampling paper by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 809(1570-0232; 1): 43-9.
82. Lindegarth N, Funding L, Bergqvist Y. Automated solid-phase extraction method for the determination of atovaquone in capillary blood applied onto sampling paper by rapid high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 758(1387-2273; 2): 137-44.
83. Blessborn D, Romsing S, Annerberg A, et al. Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper. J Pharm Biomed Anal 2007; 45(0731-7085; 2): 282-7.
84. Garcia BR, Henseler J, Mattern R, Skopp G. Determination of morphine and 6-acetylmorphine in blood with use of dried blood spots. Ther Drug Monit 2008; 30(1536-3694; 6): 733-9.
85. [Ng K, Zhou H, Zhang YL, Hybertson B, Randolph T, Christians U. Quantification of isoniazid and acetylisoniazid in rat plasma and alveolar macrophages by liquid chromatography-tandem mass spectrometry with on-line extraction. J Chromatography BAnalytical Technologies Biomed Life Sci 2007 1; 847(2): 188-98.
86. Gitau EN, Muchohi SN, Ogutu BR, Githiga IM, Kokwaro GO. Selective and sensitive liquid chromatographic assay of amodiaquine and desethylamodiaquine in whole blood spotted on filter paper. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 799(1570-0232; 1): 173-7.
87. Li PK, Lee JT, Conboy KA, Ellis EF. Fluorescence polarization immunoassay for theophylline modified for use with dried blood spots on filter paper. Clin Chem 1986; 32(0009-9147; 3): 552-5.
88. de Velde F, Alffenaar JW, Wessels AM, Greijdanus B, Uges DR. Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatographytandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877(18-19): 1771-7.
89. Cheung CY, van der HJ, Hoogtanders K, et al. Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transpl Int 2008; 21(0934-0874; 2): 140-5.
90. [Hoogtanders K, van der Heijden J, Christiaans M, Edelbroek P, van Hooff JP, Stolk LM. Therapeutic drug monitoring of tacrolimus with the dried blood spot method. J Pharm Biomed Anal 2007 07/27; 44(3): 658-64.
91. Bergqvist Y, al KJ, Krysen B, Berggren P,I, Rombo L. Highperformance liquid chromatographic method for the simultaneous determination of mefloquine and its carboxylic metabolite in 100- microliters capillary blood samples dried on paper. J Chromatogr 1993; 615(0021-9673; 2): 297-302.
92. [Lejeune D, Souletie I, Houze S, Le bricon T, Le bras J, Gourmel B, et al. Simultaneous determination of monodesethylchloroquine, chloroquine, cycloguanil and proguanil on dried blood spots by reverse-phase liquid chromatography. J Pharm Biomed Anal 2007 02/19; 43(3): 1106-15.
93. Rowland M, Emmons GT. Use of dried blood spots in drug development: pharmacokinetic considerations 1. AAPS J 2010 09; 12(1550-7416; 1550-7416; 3): 290-3.
94. Jones AW, Larsson H. Distribution of diazepam and nordiazepam between plasma and whole blood and the influence of hematocrit. Ther Drug Monit 2004 Aug; 26(4): 380-5.
95. [Hinderling PH. Red blood cells: A neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 1997 SEP; 49(3): 279-95.
96. Fleuren HL, van Rossum JM. Nonlinear relationship between plasma and red blood cell pharmacokinetics of chlorthalidone in man. J Pharmacokinet Biopharm 1977 Aug; 5(4): 359-75.
97. Emmons G, Rowland M. Pharmacokinetic considerations as to when to use dried blood spot sampling. Bioanalysis 2010 Nov; 2(11): 1791-6.
98. [Spooner N, Ramakrishnan Y, Barfield M, Dewit O, Miller S. Use of DBS sample collection to determine circulating drug concentrations in clinical trials: practicalities and considerations. Bioanalysis 2010 08/01; 2010/12; 2(8): 1515-22.
99. [Mohammed BS, Cameron GA, Cameron L, Hawksworth GH, Helms PJ, McLay JS. Can finger-prick sampling replace venous sampling to determine the pharmacokinetic profile of oral paracetamol? Br J Clin Pharmacol 2010 JUL; 70(1): 52-6.
100. Saracino MA, Lazzara G, Prugnoli B, Raggi MA. Rapid assays of clozapine and its metabolites in dried blood spots by liquid chromatography and microextraction by packed sorbent procedure. J Chromatogr A 2011 Apr 22; 1218(16): 2153-9.
101. Van Schooneveld T, Swindells S, Nelson SR, Robbins BL, Moore R, Fletcher CV. Clinical Evaluation of a Dried Blood Spot Assay for Atazanavir. Antimicrob Agents Chemother 2010 OCT; 54(10): 4124-8.
102. Newman MS, Brandon TR, Groves MN, Gregory WL, Kapur S, Zava DT. A liquid chromatography/tandem mass spectrometry method for determination of 25-hydroxy vitamin d(2) and 25- hydroxy vitamin d(3) in dried blood spots: a potential adjunct to diabetes and cardiometabolic risk screening 1. J Diabetes Sci Technol 2009; 3(1932-2968; 1932-2968; 1): 156-62.
103. Cornbleet PJ, Gochman N. Incorrect Least-Squares Regression Coefficients in Method-Comparison Analysis. Clin Chem 1979; 25(3): 432-8.
104. Allanson AL, Boyter AC, Tettey JNA, Cotton MM. Determination of anti-tuberculosis drugs in blood spots. J Pharm Pharmacol 2007; 59: 38.